(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Auschwitz Committee wants German auction of Holocaust items scrapped - 2Nitty gritty Manual for Picking Agreeable Tennis shoes
- 3Incredible Travel Objections for Craftsmanship Darlings to Visit
- 4The Best 15 Applications for Efficiency and Association
- 5How to get rid of your Christmas tree — and the 1 thing to never, ever do with it
- Nexi expands alliance with PayPal
- How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- Manual for Famous people Known for Their Altruistic Endeavors
- Experience Is standing by: History's Most noteworthy Travelers
- 7 Countries Where You Can Buy a Home for Under $100,000
- 5 Home Improvement Styles: Decision in favor of Your #1
- Holiday travel: Best days to hit the road as 110 million Americans expected to drive over Christmas and New Year's
- SF Chinatown's historic Empress of China building being revived into cultural campus
- 6 Web-based Staple Help You Can Trust
